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 Glioblastoma multiform (GBM) is one of the most aggressive forms of primary 
brain tumors. GBM is fast progressing and resistant to treatment, resulting in a low survival 
rate. Conventional 2-dimensional tissue culture models cannot fully replicate the 
complexities of cancer lesions that contain multiple cell types and structures (e.g. vessels 
composed of endothelial cells, cancer cells, normal cells, etc.) as well as an intricate 
scaffold of proteins comprising the extracellular matrix (ECM). In addition, animal models 
cannot translate into the clinical disease in patients. Thus, this study has developed a 
bioprintable organ-on-a-chip (OOAC) model that mimics the important ECM factors of the 
GBM tumor microenvironment to study GBM invasive migration in vitro. Gelatin 
methacrylol (GelMA), endothelial cell (HUVEC) lined channels, human GBM cells (U87) 
and hyaluronic acid (HA) were selected to create bioinks to print the OOAC. 5-7% (w/v). 
GelMA with variable levels of HA was found to be mechanically comparable to native 
ECM of the brain. Different bioink combinations were explored to match the Young’s 
modulus of common GBM tumors found in literature. Spreading of endothelial cells in a 
microfluidic channel were observed with a monoculture OOAC, and a viable bioink 
composition and culture method were developed to support co-culture in the OOAC. Our 
diseased tissue model can replicate the GBM ECM and can allow for multi-cell culture 
migration studies in the future. 
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Introduction and Background 
1.1. Introduction and Background 
Over 1.7 million new cancer cases are diagnosed in the US each year, which is 
4,700 new cancer diagnoses each day [1]. Within the past few decades, there have been 
discoveries in new forms of cancer treatments, understanding cancer pathways, and a 
broader understanding of cancer metastasis. Primary brain tumors have a high mortality 
rate with the most lethal sub-type being Glioblastoma multiforme (GBM), with more than 
30,000 new cases every year [2], [3]. The median survival rate for patients with this disease 
is approximately 15 months [3]–[5]. There is a lack of proper treatments because of feasible 
pre-clinical models that can provide information to develop new forms of therapeutics. 
Engineered models have the potential to accurately mimic the GBM microenvironment 
outside of a patient’s body, allowing for better tools for research [6]. 
1.1.1. Problem statement. GBM patients suffer from poor prognosis attributed to: 
(1) tumor location; (2) blood brain barrier and drug uptake; (3) aggressiveness; and, (4) a 
lack of relevant preclinical models for drug development [2], [3], [5]. Complete removal 
of the tumor is difficult due to the location of the tumors, as the tissue can be a part of key 
neurological functions and full removal is not always beneficial for quality of life [2], [5]. 
Results tend to be modest due the aggressive nature of GBM. This contributes to the poor 
prognosis of GBM, which is recognized as an orphan disease by the World Health 




Current pre-clinical GBM studies consist of in vitro cell culture methods and 
animal models. Two-dimensional (2-D) cell culture models are relatively inexpensive and 
allow for real time imaging; however, they lack the three-dimensional (3-D) complexity of 
GBM in vivo. Animal models provide in vivo complexity that is not possible with in vitro 
monolayer models [7]–[11]. Animal models have different tissue mechanical properties 
and metabolism, are expensive, time consuming, and limited data points can be collected 
[8], [11], [12]. To address this, there has been a movement towards utilizing 3-D bioprinted 
models to study behavior in vitro [8], [13]–[17]. It has been found that for GBM, utilizing 
a model that has multiple cell lines and a synthetic extracellular matrix (ECM) allows for 
behavior similar to in vivo tissue [18]–[20]. For lung cancer there has been a successful 
model that can monitor and track invasion of cancer cells towards endothelial lined 
microfluidic channels that mimic malignant invasion in vitro [21]. There is currently no in 
vitro co-culture GBM model that mimics the ECM and invasive migration towards 
endothelial lined channels.               
 1.1.2. Significance of study. In the US, there are currently 700,000 people who are 
living with a brain tumor. In the year of 2020, an additional 87,240 people will receive a 
primary brain tumor diagnosis [22]. Of that number, 25,800 people will be diagnosed with 
a malignant brain tumor [22]. Only 36 % of patients will survive the 5-year treatment, and 
only 6.8 % of patients with GBM will survive the 5-year treatment [1], [22]. It is estimated 
in 2020, that 18,000 people will die from malignant brain tumors [1]. Pediatric brain tumors 
are also the leading cause of cancer-related death surpassing leukemia, and 4.3 % of all 
malignant brain tumors are diagnosed in children 0-14 years old [22]. It is the third leading 
cause of cancer-related death for adolescent age groups (15-29) [22]. 
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Our OOAC has the potential to be used as a tool to monitor behavior in vitro that 
is comparable to in vivo. Similar OOACs for other cancer lines have been used for: a 
screening tool for new treatments, for toxicity testing of treatments, and in studies to 
understand better understand cell behavior [8], [9], [21], [23]. This model could impact the 
design of new treatment strategies for pharmaceutical and biomedical devices. This OOAC 
model would be used as an in vitro GBM invasive migration utilizing by replicating the 
ECM environment that can be monitored in real time. 
1.2. Glioblastoma Multiforme 
1.2.1. GBM environment. Glioblastoma is a destructive solid tumor that forms in 
the brain,  which infiltrates into surrounding brain tissue [2], [19], [24].An important 
component of this tissue is the extracellular matrix (ECM). The brain ECM has a unique 
composition and lacks the rigid matrix of fibronectin and laminin that is typical of other 
tissue [25], [26]. Instead, brain intercellular spaces are filled by proteoglycans [27], [28], a 
class of water binding proteins produced by astrocytes and oligodendrocytes. It is formed 
with a network of macromolecular proteins of collagen IV and elastin; this matrix is 
enriched with hyaluronic acid (HA). HA contributes to structural support and regulate 
intracellular signaling [26], [31] and is associated with cytokines involved in proliferation 
and inflammation [29], [30]. 
The other key components of the surrounding environment are comprised of 
astrocytes (healthy brain cells), neurons, endothelial cells (blood vessel lining), 
oligodendrocytes (a part of CNS function), pericytes (outside encasement of endothelial 
cells), and vascular basement membrane (barrier between vascular and surrounding extra 











1.2.2. Hyaluronic acid. The concentration of HA in the ECM of GBM-afflicted 
tissue has been found to be elevated compared to healthy brain tissue [24], [31], [34]. A 
contributor to this phenomenon is that glioma cells increase the amount of HA receptors, 
which plays a role in cell migration and invasion  [29], [29], [30], [35].  The presence of 
HA has been shown in vitro to increase proliferation and invasiveness [29], [32], [36]. 
Common materials that have been used as a base for in vitro brain ECMs are gelatin 
methacrylate and hyaluronic methacrylate [11], [12], [37], [38]. Gelatin and HA are shown 
to provide support that the ECM typically provides as well as aid in maintaining cellular 
function [38], [39]. The addition of the methacrylate group to gelatin allows for the material 
to be crosslinked via ultraviolet light (UV), allowing for precise patterning and bypassing 
the thermosensitive natures of the materials [12]. The presence of HA has been found to 
improve the viability and function of astrocytes and GBM in vitro [35], [40], [41]. As such 
the presence of HA is highly desired when working on an in vitro model. 
 1.2.3. GBM stiffness. GBM has been found to strongly express HA and HA 
receptors, such as CD44 [24], [34].. It has been hypothesized that since CD44 increases 
proliferation, it acts in a symbiotic cycle resulting in a higher concentration of GBM cells 
[37], [38]. As the tumor becomes bigger, more destruction of the surrounding tissue occurs, 
which could cause the slightly lower mechanical properties of the tissue [22], [28], [45], 
[46]. Studies have been conducted on brain tissue and different forms of primary brain 
tumors in order to get an idea of the magnitude of changes of the mechanical properties. 
Young’s moduli were collected from samples of cancerous and healthy brain tissue from 
human patients. Healthy human brain tissue has an average Young’s modulus of 7.3 ± 2.1 
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kPa [45]. In addition to healthy brain tissue two forms of gliomas were tested: low-grade 
gliomas (23.7 ± 4.9 kPa) and high-grade gliomas. 
1.2.4. Blood brain barrier. Blood vessels in the brain have a highly selective and 
controlled barrier known as the blood brain barrier (BBB) [28], [42]. This selective barrier  
reflects the brain's critical roles in cognition, regulating metabolism, and coordinating the 
functions of peripheral organs [42], [43].  The BBB is a semipermeable border between the 
brain and the outside tissue. It controls ions traveling across the brain, ensuring that proper 
function can be maintained [27], [42]. This barrier prevents nonselective travel of solutes, 
cells, and toxins from accessing the CNS extracellular fluid. The BBB is a complex that 
surrounds most blood vessels within the brain. The first layer is comprised of tight junction 
endothelial cells which prevent the passage and diffusion from the blood to the surrounding 
space. The next basement membrane layer is comprised of pericytes and vascular smooth 
muscle cells (VSMCs), which incompletely surround the blood vessel. Pericytes and 
VSMCs provide contractile function to control vessel diameter [43]. Surrounding this layer 
is the basement membrane which acts as an additional barrier between the blood vessels 
and the ECM.  The outer layer is formed with the astrocytic feet of astrocyte cells, which 
completely surround the blood vessels and aid in keeping the junctions tight, and which 
promote endothelial cells to form the BBB barrier [42]–[44]. This layered formation of 














1.3. In Vitro GBM Models 
Many methodologies have been developed to address the need for research in 
glioblastoma multiform (GBM). These methodologies include:  2-D monoculture, multi-
culture, chemical gradients, culture substrates, microfluidic models, and combinations of 
these factors[2], [35], [46], [47]. GBM is an aggressive form of brain cancer, as such it is 
important that any model developed can replicate some of the phenotype behavior observed 
in vivo. An overview follows of   some of these methods and the models that were 
developed to replicate cancer metastasis, GBM biology, and cell-to-cell interactions.  
1.3.1. 2-D GBM models. Traditional cell models are comprised of a 2-D cell 
culture, which is often done on glass or treated polystyrene. This stiff material encourages 
cells to adhere, proliferate, and move across the surface. Monoculture 2-D models have 
emerged to study many concerns associated with GBM[31], [35]. This method has been 
utilized for: whole genome sequencing [2], drug screening of GBM phenotypes,  [46], 
implants for animal models,  [48] and studying cell signaling[30], [31], [35].  
1.3.2. 3-D GBM models. With the emergence of technology and understanding of 
cancer metastasis, there has been a push towards developing 3D models for cell culture [8], 
[49], [50]. One of the benefits with 3D cell culture is utilizing substrates that are biomimetic 
to the in vivo tissue environment [24], [50]. One approach often used to achieve this is a 
biocompatible hydrogel that has properties that are biomimetic to native tissue[11], [17], 
[50]. This has been shown to increase cell growth, develop a complex cellular environment, 
and elicit invasive behavior [15], [49], [51], [52].  
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1.3.3. GBM OOAC models. Many OOAC models have been produced in 2-D and 
3D to try to create a better cancer model, often with a goal to capture the cancer cascade 
and study  invasion[8], [13], [23], [47], [53].  
OOAC contain a microfluidic channel in which media with nutrients are supplied 
to the surrounding cells [8]. Studies have shown that microfluidic flow, mechanical 
properties, and the presence of cells affect invasiveness [8]–[10], [19]. The presence of 
multiple cell lines in OOAC models have shown to better mimic the tumor 
microenvironment and progression of an in vivo environment [2], [10], [21], [23], [47], 
[54].   
Microfluidic channels within OOAC are a critical factor to ensure in thicker 3D 
constructs ample nutrients and supplies are delivered throughout the system. These 
channels are formed through the use of molds or through the use of sacrificial material [7], 
[17]. Sacrificial materials that can be removed through temperature or chemical 
interactions are more common when developing OOAC through bioprinting [55]. This 
allows for small capillary-sized channels to be left within more complex structures that are 
more difficult to achieve via molds [55], [56]. 
When utilizing OOAC for co-culture systems, seeding endothelial cells within 
microfluidic channels with the presence of shear flow, has been shown to help form a lumen 
in vitro[21]. Endothelial lined microfluidic channels are mimetic to vasculature in vivo 
[21], [57], [58] and in co-cultures with cancer lines causes increased invasive behavior [9], 
[18], [44], [54].  
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1.4. 3-D Tissue Modeling Methods 
The field of tissue engineering has emerged in recent years in order to meet the 
needs of 3D cell culturing. Tissue engineering is designed to model or replace different 
tissues in the body [8], [11], [59]. This is achieved through the use of biocompatible 
biomaterials, cells, or a combination of both [54], [59], [60]. Table 1 provides an overview 
of the main assembly methods and the related aspects of each type of tissue engineering 
methods [11]. 
 
Table 1  
 
Comparison of engineering pre-clinical models [19] 
 
 
As shown in Table 1, each method has its own advantages and disadvantages.  
Bioprinting has the highest resolution among the three methods, and allows for precise cell 
and material patterning [8], [11], [59]. In both tissue engineering and in vitro modeling, 
utilizing these microenvironments help more effectively reproduce features of an in vivo 
tissue environment compared to a classic 2-D cell culture. This method of fabrication has 
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been utilized in a large variety of applications including tissue engineering, drug delivery, 
oncology models, wound repair, tissue replacement, and bioreactors [8], [11], [59]. 
1.4.1. Bioink. In bioprinting, materials that are used for the printing process are 
known as bioinks. They often are biocompatible or inert polymers that are used to print for 
biological purposes. Common materials for bioinks consist of: alginate, gelatin, 
decellularized ECM, and Pluronic [11], [55], [60]. Often, bioinks need to be crosslinked in 
some fashion to maintain the printed shape for an in vitro or in vivo testing environment. 
This is accomplished through a few methods including chemical crosslinking, UV 
crosslinking, and thermal gelation. Chemical crosslinking is when some component of the 
biomaterial interacts with a chemical to crosslink the material (i.e. alginate and calcium 
chloride) [8], [59], [61]. In UV crosslinking, a photoinitiator (PI) is added to the bioink and 
exposed to a UV light, which then crosslinks the material [5]. Some common UV 
crosslinked bioinks are those with a methacrylate group, such as gelatin methacrylate 
(GelMA) or hyaluronic methacrylate (HAMA) [8], [37], [59]. UV crosslinking usually 
does not affect cell viability in this method [61]–[63].  
1.4.2. Bioprinting approaches. Three-dimensional bioprinting may be broken 
down into four main categories: extrusion printing, inkjet-based printing, laser assisted 
printing, and photocured printing. Within each of these subcategories each have their own 
strengths and limitations, and are intended for different applications. All of these methods 
utilize some type of bioink and require some form of crosslinking. In some systems, the 
crosslinking is accomplished during the printing process. Other methods require 




 Comparison of bioprinting methods [65] 
 
 
1.4.3. Extrusion bioprinting. Extrusion is utilized in many forms of 3D printing. 
The most common place is fused deposition modeling (FDM). FDM uses heat to melt the 
printing material (e.g. PLA, ABS, etc.), that is then printed and cooled into the desired 
shape. For 3D bioprinting, this is achieved with a combination of a fluid-dispensing system 
and an automated motion system [8]. 
1.4.4. Inkjet bioprinting. Inkjet-based bioprinting is similar to 2-D inkjet printing. 
A bioink solution is stored within ink cartridges connected to a printer head. The material 
is then extruded droplet-wise by deforming the printing head. This is often done by an 
actuator that is squeezed to generate droplets of a controllable size [19], [28], [53], [66]. 
Within this bioprinting method, there are two methods in which bioink printing is achieved: 
continuous ink jetting and drop-on-demand. 
1.4.5. Light based bioprinting. Laser-assisted bioprinting was developed from 
laser direct and laser-induced transfer technologies [18], [67]. Laser-assisted printing 
comprises of two layers: a donor layer and energy absorbing layer. The donor layer 
responds to a pulsed laser beam with a focusing system. This is supported by a ‘ribbon’ 
that is typically made from glass and has an energy absorbing layer (e.g. gold or titanium) 
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[67]–[70]. This donor layer is a part of two material layers. It is positioned on top of a 
bioink layer, and when the laser-assisted device pulsates on the donor layer, a high-pressure 
bubble is formed [68]–[70]. When this bubble is formed, the force will propel the cell-




Figure 3. Diagram of laser assisted bioprinting [66] 
 
In laser assisted bioprinting, the laser is a coherent light source. As a result, this 
printing process tends to be one of the most expensive. It utilizes excimer argon fluoride 
(ArF), krypton fluoride (KrF), or neodynmium-doped yttrium aluminum garnet (Nd: YAG) 
to act as a laser pulse generator. There are no devices commercially available on the market 
for this printing process [11], [50], [64]. This process achieves a high cell viability (>95 
%), has a medium print speed (200-1,600 mm/s), and can handle a good range of viscosities 
[11], [65]. Cell density tends to be at a medium for the four main printing methods, 
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typically <108 cells/mL [11]. Due to this method being able to have high precision of cell 
density and alignment in the droplet formation, [14], [64] this method invites some novel 
applications. It is one of the first bioprinting methods to successfully conduct in vivo 
bioprinting. There was a case where mesenchymal stromal cells were used to replace a 
mouse calvaria, and the print was made directly onto the defective tissue [14]. This method 
has also been utilized in carcinoma with microvasculature [64], cardiac tissue [50], 
cellularized skin constructs [50], and adipose tissue [11]. 
UV-based methods can be divided into three sub categories: stereolithography 
(SLA), digital light processing (DLP), and digital micromirror devices (DMD) [11], [61], 
[66], [67]. In all UV-based printing techniques, a print bed is submerged in a liquid 
photocurable resin, or a bioink in tissue engineering cases. Stimulation by UV light 
crosslinks the material onto the print bed [5], [20]– [23]. In SLA, a computer-controlled 
light beam fabricates material vector-by-vector in a bottom-up approach [24]. DLP is 
where a UV light source is projected onto a transparent surface, within a vat of 
photosensitive bioink. As a result, the entire layer is crosslinked upon light exposure [20], 
[23]. Original attempts with DLP included using physical masks applied to the light source 
to define the pattern for each shape [11], [60], [61], [67].  
DMD-based printing is an improvement on the DLP method and thus is a subset of 
DLP-based bioprinting. In this method, a DMD device provides a dynamic pattern 
generator allowing for more variability and higher resolution [62], [66]. Within the DMD, 
thousands of mirrors are precisely controlled through computer aid, which can allow for 
the light to be reflected in the exact desired pattern, layer-by-layer [55], [62], [66]. This 
method can result in a precisely defined resolution, achieving in literature as small as 5 μm 
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in the z-axis [68]. Figure 4 below provides a graphic image for how SLA and DMD-based 
DLP bioprinting is achieved [61], [62], [65]–[67].  
 
 
 Figure 4. Comparison of SLA and DLP printing methods [68] 
 
 
Most of these printing systems are configured through a top-down projection. 
However, it has been found that a bottom-up projection approach can provide a higher 
resolution, material conversation, and quicker print time [52], [69]. This method has a 
relatively low cost, good cell viability of (>85 %), and has no limitation of the viscosity of 
materials. Typical cell density for this process is <108 cells/mL [55], [66], [69]. Its speed 
is fast comparable to ink injection and is determined by the bioink material and type of 
photoinitiator used [11], [59], [69]. These methods have been used in a wide variety of 
processes including blood vessel [11], meniscus repair [68], carcinoma [70], [71], and 
OOAC [11], [21], [67].  
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1.5. Bioink Composition 
In 3D bioprinting, hydrogels are commonly used to print out these structures. One 
common biomaterial is GelMA, which is often used as it has a high degree of quality 
control as well as physical and mechanical properties similar to tissue [58], [72], [73]. In 
addition, it has been found to be an excellent substrate and has shown successful 
angiogenesis and cell growth [74]. GelMA is formed with gelatin and methacrylic acid. 
Gelatin is primarily composed of collagen and elastin monomer chains that are found in 
most tissues. Since gelatin is thermosensitive, then without any alterations, placing gelatin 
structures at incubator temperatures (i.e. 37-40 oC) results in monomer chain relaxation 
and a liquid state. GelMA presents an altered structure of gelatin. Gelatin and methacrylic 
acid react to form methacryloyl groups. When a photoinitiator is added to GelMA and it is 
exposed to UV light, a tangle of the monomers of the gelatin hydrogel matrix is induced 
that retains tissue-like properties and structure [37], [38], [73], [75], [76]. Typically to 
replicate human tissue, GelMA ranging from 5-10 wt % is used. The amount of methacrylic 
acid, source of gelatin, and molecular weight of gelatin have an effect on the viscoelastic 
properties of the GelMA [77]. This degree of customization allows for precise tuning of 
the material for bioprinting applications [15], [38], [67], [68], [73]. Other types of 
naturally-derived polymers can be formed the same way. There has been an emerging use 
of hyaluronic methacryloyl, either on its own or in conjunction with GelMA, to provide 
structures that have a higher hyaluronic acid concentration for use with certain tissues [25], 
[32], [53]. 
1.5.1. Cell laden bioinks. In 3D cell constructs it is often desirable to have precise 
patterning for cell culture purposes. The ability to have localized cell positioning, or 
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equally suspended cells throughout the construct is ideal [11], [73].The main method to 
achieve this is to prepare bioink that have cells suspended throughout the printing medium. 
This is often done with soft or thermosensitive materials that can allow for mixing at 
warmer temperatures, and solidify later through crosslinking. Often, bioinks that are 
biocompatible are highly desirable to prevent cells from being damaged during the pre-
printing and post-printing process. This is necessary for multiculture structures, as multiple 
bioinks can be prepared that allow studies of processes such as metastasis [11], [17], [78].  
1.6. Materials and Methods 
1.6.1. Project goals. The overall goal for this model was the development of   an 
in vitro co-culture model. Ideally the model would have replicated the GBM ECM 
mechanical properties, to study the effect on cell migration and invasion. Customized 
bioinks and printing parameters that mimic native ECM mechanical properties were 
developed. This model was a bioprinted microfluidic model composed of a co-culture of 
GBM cells and endothelial lined channels. The chip was constructed to allow for 
monitoring in real time of cell migration. The chip was made with a customized DLP 
bioprinter.  The initial goals were for this was to produce a comparable bioink to native 
ECM, successfully line microfluidic channels with endothelial cells, produce a system that 
can support co-culture, and to test   a novel bioprinting. At this time the model is a co-
culture so without the presence of astrocytes, it lacks the formation seen for the blood brain 
barrier. In addition, simplified channels were used as leaky vasculature is not considered 
at this time. 
1.6.2. Cell culture. Immortal human glioblastoma cells (U-87: MG cell line, 
ATCC, USA), cell size range 12–14 μm (B10NUMB3R5: bionumbers.hms.harvard.edu), 
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were cultured in BD EMEM (Becton, Dickinson and Company, Miami, FL, USA), which 
was prepared with 10 vol% fetal bovine serum (ATCC 30-2020). Cells were cultured in 
T75 flasks that were fed every two days and passaged with 1 mL of trypsin-EDTA solution 
(0.25% Corning, Manassas, VA). 
Human umbilical vasculature endothelial cells (HUVECS), cell range 14–15 μm 
(B10NUMB3R5: bionumbers.hms.harvard.edu), were cultured with an EGMTM-2 
Endothelial Cell Growth Medium-2 BulletKitTM (Lonza CC-3162). Cells were seeded in 
a T75 flask and were fed every two days and passaged with 1 mL of trypsin-EDTA solution 
(0.25% Corning, Manassas, VA). As a primary cell line was utilized, cells for experiments 
were used before the 10th passage.  
1.6.3. GelMA preparation. Gelatin, 10 g, (Type A from porcine skin, Sigma-
Aldrich, G1890) was dissolved into Dulbecco's Phosphate Buffered Saline, DPBS, 100mL 
(SAFC, Sigma-Aldrich, 56064C) solution by heating on a magnetic stirring plate for h 
60°C until the solution was clear and homogenous. Methacrylic anhydride (MA), 8 mL, 
was added drop-wise into the solution and then heated at 50 °C for one hour. The pre-
warmed (40 °C) DPBS was added to the solution, 500 mL, to stop the reaction. Dialysis 
tubing (12-15 kDA) was cut to a length of 8 in and immersed in deionized (DI) water for 
15 min. A knot was made at the end of the tube, and 30 mL of solution was then pipetted 
into the dialysis tubing until all tubing was filled with solution. Dialysis tubing was placed 
in DI water for one week at 40 °C, with the water changed twice daily. After a week, 
solution was collected in a glass flask and sterile filtered (pore size of 0.22 µm). Then 
45mL of solution was transferred into a 50 mL Falcon tube and placed in a -80 °C freezer 
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for 24 h. The solution was prepared for freeze drying and freeze dried for 48 h. It then was 
stored at -80°C until use. 
1.6.4. Bioink preparation. GelMA solution at the desired weight percent was  
heated in a magnetic stirring plate for 1 hour at 40–60 °C until the solution was clear and 
homogenous. The solution was sterilized in a biosafety cabinet via a syringe filter (0.2 μm 
PES, VWR). For bioink preparation, the cells were counted using 20 μL of Trypan Blue 
Stain (0.4%, EVE, Stretton, UK) and an automated cell counter (RevCount Cell Counter, 
Oxford, CT, USA). Cell solutions were diluted to the desired cell density by adding pre-
warmed gelatin solution. Samples were gently agitated until cell pellets were dispersed 
through gel solutions. 
1.6.5. Rheometer experiments. Rheological measurements were performed 
using a DHR Hybrid Rheometer (TA Instruments) with a flat-plate geometry measuring 
system (Plate SST ST 40 MM Smart Swap, Part Number 511400.905, UK), utilizing a 
parallel-plate geometry. Experiments were performed at 20 °C for the selected cell 
densities 50 million (M), 5 M, and 0.5 M cells/mL. To ensure that cells were uniformly 
distributed, solutions were kept in a water bath (37 °C) and each sample was gently 
agitated before pipetting the sample onto a rheometer plate. The optical opaqueness of 
gelatin provides a good criterion to assess uniform distributions of cells. Before each test, 
the samples were cooled to room temperature through the temperature control unit in the 
rheometer. First was a flow ramp test which measured shear stress (τ, Pa), normal stress 
(σ, Pa), and steady shear viscosity (η, Pa. s) by changing the shear rate (1 to final 103 
s−1). Second was an oscillation test (not shown here), conducted using a strain percent of 
2%, and a linear sweep angular frequency from 1.0 to 100.0 rad/s to measure the storage 
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modulus (G′), loss modulus (G″), and phase angle (θ°). Next, the viscosity of a non-
Newtonian fluid can be defined by a power law [78]: 
η = K ∗ γ𝑛          (1) 
where γ is the shear rate, K is the viscosity coefficient, and n is the power law index. The 
parameters K and n can be obtained from the regression of rheological data [78]. 
  1.6.6. Mechanical experiments. Compression tests were carried out with a 100 N 
force tester with a Shimadzu, EZ-SX Short, (Columbia, MD, USA) machine unit. 
Compression tests were conducted with a 1 mm thick, 10 mm wide, crosslinked GelMA 
disc with the Shimadzu compression program at strain rates of 0.1 mm/s. 
  1.6.7. Live/Dead experiments. The bioink solutions were extruded by hand  
with a 5 mL syringe with a 25 G needle into a glass container. Live/Dead staining kit was 
prepared (PromoKine Live/Dead Staining Kit II, Heidelberg Germany) and performed 
following the standard protocol. Then, the samples were imaged using confocal 
fluorescence microscopy (Olympus IX-70 with Thorlabs Confocal Microscopy Upgrade, 
USA). Images were processed with ImageJ (FIJI) software[79]. 
1.6.8. Statistical analysis. All results were presented as the mean ± standard  
deviation (SD). Statistical analysis was performed in Microsoft Excel using one-way 
analysis of variance (ANOVA) in conjugation with a Bonferroni post-hoc test. Three 






2.1. Mechanical Properties 
Mechanical properties of tissue extracellular matrix (ECM) have a significant impact 
on the behavior of cells. These mechanical properties are attributed to collagen, elastin, 
cells, and other biological components that make up the structure of the ECM. To replicate 
in vivo environment, one common material type is water-saturated polymer-like hydrogels 
[17], [60]. Among different hydrogel systems, GelMA represents a similar composition to 
human ECM in soft tissues. GelMA over the range of 5-10 wt% prepared with a phosphate 
buffered saline (PBS) closely replicates human ECM [15], [38], [74], [77]. 
The mechanical properties of the material selected for printing is very important when 
having an accurate cellular response. Particularly with tumor tissue, there is an increase in 
the elastic properties compared to native healthy tissue [80]–[82]. This property has been 
shown to drive invasiveness and affect cell migration [82].  
For our experiments, bioink comprised of cell-laden GelMA was used. There have been 
extensive studies on the ranges of GelMA correlating to tissue ECM. However, the effect 
of cell density on the mechanical properties of bioinks in 3D bioprinting has not been 
extensively explored. The mechanical properties of tissue ECM have a key interaction with 
GBM. Higher grade tumors seem to experience a change in mechanical properties, as such 
cell density may also have an effect on the GelMA substrate. To better understand this 
relationship, shear rheology measurements were conducted on GelMA and culture media-
based bioink compositions.  
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2.2. Rheometer Experiments 
 2.2.1. Rheometer cell experiments. Intracellular adhesion, colloquially known as 
the “stickiness” among cells, allows for GBM to invade the smallest spaces within the 
brain. Samples were prepared in three concentrations of GBM cells suspended in culture 
media: 50 million cells/mL (50M), 5 million cells/mL (5M), and 500 thousand cells/mL 
(500K). The rheological tests included: 1) shear force measurements for a sweep of loading 
frequency, and 2) dynamic viscosity measurements for a range of shear rates. The 
rheometer tests were conducted at 37 ⁰C to replicate the environment of the human body. 
The data was collected in the machine software and then represented by three different 
parameters: 
Storage modulus: Material’s ability to store elastic energy, E’ 
Loss modulus: Material’s vicious properties, represents amount of energy lost E”  





Figure 5. Rheometer data of cell laden media at 37 ºC: A) Storage modulus of cells 
suspended in media; B) Loss modulus of cells suspended in media; C) Dynamic 
viscosity of cells suspended in media. All data collected from a dataset of 48 samples. 
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Compared to basal culture media, the inclusion of cells increases bioink viscosity 
versus shear rates in a statically significant manner (p = 0.0096). This is different for the 
case of the storage modulus and loss modulus frequency as it was found to not make a large 
statistical difference between cell laden materials and a control (p = 0.71 and p = 0.65 
respectively for 50K cells/mL). Viscosity under test conditions increases as cell 
concentration increases; however, loss modulus was not affected by an increase in cell 
concentration. A visual trend where acellular media was present has the lowest values for 
viscosity, storage, and loss modulus. As cells were added to media these values increased. 
500K cells/mL had the lowest values excluding the acellular media in storage modulus, 
loss modulus, and viscosity. 50K cells/mL had the highest storage and loss modulus values 
when compared to the other testing conditions. However, it had a lower viscosity value 
compared to the 5M testing condition. These observations denote that GBM cells may 
exhibit viscoelastic properties, with the elastic portion observed at lower angular 
frequencies. Native brain elasticity increases when glioblastoma affects the tissue; our 
results show that the cell density within tumors may contribute to the elasticity found in 
GBM afflicted tissue.   
2.2.2. Cell laden bioink experiments. Cell volume, physical cell interactions, 
viscosity of the matrix, and cell spatial arrangements can impact bioink printability [64], 
[78]. In order to investigate the role of cells on the shear rheology, experiments were 
repeated with cell laden GelMA-based bioinks. (Due to preparation costs, we replaced 
GelMA with gelatin due to their similarity of the physical properties.) GelMA at 7 wt% 
was used for the rheology experiments. The control, which has no cells present, exhibited 
the highest values of shear stress and viscosity. As cells were added to the bioink, the 
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viscosity and shear stress decreased.  In addition, a left shift was observed for the shear 
stress values for cell-laden bioink samples. The lowest values occurred at 5 M cells/mL, 
and values increased at 50 M cells/mL.  
The viscosity data in Figure 6A was then fit to the power law formula and analyzed 
through linear regression for each cell density test condition. The regression results will be 
discussed later. Cell volume, physical cell interactions, viscosity of the matrix, and cell 
spatial arrangements all have an effect on bioink printability [64], [78]. In order to 
investigate if the same trends occur as observed for media-based bioink, experiments were 
repeated with GelMA-based bioink. GelMA at 7 wt % was used for the rheology 




Figure 6. Shear rheology data for cell-laden bioinks (7 wt % gelatin): A) Mean steady 
shear viscosity versus shear rate (1/s), and B) Mean shear stress versus shear rate (1/s) for 
different concentrations of U87 cells, where “Control” means 0 cells/mL. Data are 
averaged from 48 samples. Figure adapted from [78]. 
 
Statistical analysis was conducted using ANOVA to determine which testing condition 
had a higher impact on viscosity and shear stress values. The presence of cells had a 
statistically significant effect on viscosity and shear stress values. Compared to the control, 
all cell-laden testing conditions were statistically significant different than the GelMA 
control condition. As observed in Figure 6, a higher viscosity in the control group was 
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observed as compared to cell-laden groups. For example, bioink viscosity decreased about 
40 % for the cell density of 5 M cells/mL at the shear rate of 10 s−1 (Fig. 6A). The 
difference between cell-laden and control groups was lessened in the case of 50 M cells/mL 
(~25 %, p = 0.040). Thus, it was postulated that interactions among cells superseded the 
void-like weakening mechanism of cells at lower densities. Conclusively, there was a cell 
density concentration that above the shear-thinning behavior was enhanced and remained 
nearly constant compared to the control (no cells). The cell density used in 3D bioprinting 
experiments ranges between 0.5 M and 5 M cells/mL  [78]. Many forms of 3D bioprinting 
resolution depends on the steady shear viscosity of bioinks [55], [83]. Slight viscosity 
variations can hamper the resolution of bioprinted constructs. 
Bioink viscosity depends on the spatial distribution of cells and their interactions with 
hydrogel precursors [78]. The space among cells and interspace within the hydrogel 
network was influenced by cell volume. By increasing cell density, the gaps among cells 
and cell-gel interspace decreased. This affected the behavior of hydrogel systems under 
physical deformation.  
In non-Newtonian viscoelastic solutions, a shift from solid-like behavior occurs when 
the elastic network breaks up and begins to flow. The shear stress leading to the network 
dissociation is called yield stress. The yield stress is reached when the shear stress is 
sufficient to cause the gel network to break up, and after this point the gel behaves like a 
fluid. The yield stress in gelatin solution was determined to be lowered by cell 
encapsulation (Fig. 6B). To further investigate this trend, the yield stresses for four 
concentrations were calculated and summarized in Table 3.  
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Over 40 % shift in the yield shear stress was observed for the cell-laden bioinks when 
compared to the control samples. The correlation between the cell density and yield stress 
is similar to the case of steady shear viscosity. The highest cell density exhibits the highest 
yield stress among the cell-laden data. This phenomenon can be attributed to the loose 
connections among neighboring chains as the cells may block their direct contact. This 
further supports the observation on the rheological data where encapsulating cells act as 
softening particles. Data has been adapted from published research [78]. 
 
Table 3  
 











0 356.52 0.820 1.26 ± 0.45 96.40 ± 3.35 
0.5 206.64 0.804 0.79 ± 0.34 83.96 ± 2.65 
5 173.73 0.795 0.69 ± 0.07 72.06 ± 4.90 
50 225.99 0.798 1.00 ± 0.08 68.69 ± 2.30 
 
2.3. Mechanical Testing of Photo-Crosslinked GelMA 
Mechanical testing was conducted under three different testing conditions to represent 
different GBM disease states. This was executed to confirm if the properties of the prepared 
3D constructs were comparable to that of native tissue. An initial selection of 7 wt % 
GelMA was chosen as a base formula. Prior research had found that between 5-10 wt % 
was comparable to human tissue [38], [84]. Elastic moduli are dependent on GelMA weight 
percent composition, UV exposure, percentage of photoinitiator (PI), and level of 
methacrylation. As such, it is important to confirm if the mechanical properties would be 
comparable to native tissue of a healthy brain and glioma tissue.  
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Experimental conditions for the three disease states were the following: healthy tissue 
(7 wt % GelMA + no HA), Mild GBM (7 wt % GelMA + 0.1 wt % HA) and Severe GBM 
(7 wt % GelMA + 0.05 wt % HA). In this experiment, initial results were tested with a 
strain rate of 0.01 mm/min to be directly compared to the data collected from patient data 




Mechanical testing on crosslinked GelMA with and without HA 
Sample Name HA % Elastic Modulus (kPa) Strain Rate (mm/s) Exposure (s) 
GelMA Control 0 1.7 0.1 5 
Low HA 0.1 24.6 0.1 10 
High HA 0.5 3.1 0.1 5 
High HA 0.5 4.0 0.1 10 
 
Table 4 shows that the majority of the mechanical property values were not within 
range of glioblastoma tissue[80]. Experiments were planned for 5, 7, and 10 wt % GelMA 
at five strain rates of 0.1, 0.3, 0.5, 0.8, and 1 mm/m. The reason for selecting these ranges 
of values was to determine which parameter had a dominant impact on material properties. 
Once a basal parametric combination was chosen, HA composition values were to be added 
and tested. This would show how comparable the hydrogel would be to native tissue. 
However due to COVID19 evacuation orders during 2020, experiments were halted and 







3.1. Initial Bioprinting Experiments 
Experiments were executed using a customized DLP printer (Miri Lab). Samples were 
crosslinked using a ~ 380 nm wavelength light source (light power < 500 mW/cm2), at 1 
mm thick per sample layer (< 5 s exposure time). The printing process led to a 2-D 
resolution of ~ 20 μm and a maximum fabrication region of 19 mm x 12 mm. A thick single 
layer configuration was selected in order to allow for sufficient space for cells to be 
distributed through the crosslinked material. This also minimized the effect of the glass on 
cell behavior as much as possible. As this was a customized printer setup, a study was 
conducted to ensure that the different components of printing would have minimal 
detrimental effect to cell viability. The testing conditions were: material composition, UV 
wavelength, photoinitiator ratio, and UV excitation energy. To address this, a study was 
conducted at a few different test conditions to observe and measure the effect on cell 
viability after printing. 
3.2. Photoinitiator (PI) Toxicity 
The first experiment conducted in the custom DLP printer tested whether photoinitiator 
(PI) concentration had an effect on cell viability. Cancer cell line (U87) at a concentration 
of 500K cells/mL were encapsulated in pre-sterilized GelMA with and without PI. Cells 
were incubated with both groups for two hours before images were collected by a light 
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microscope. This was done to allow time for live dead stain to permeate gel and for cells 




Figure 7. U87 cells after 2 h of exposure to PI: A) 500K cells/mL in GelMA with no PI; 
B) 500k cells/mL in GelMA with PI concentration of 0.05 wt % 
 
 A 0.5 mm depth of each sample was imaged here. In both cases, minimal cell death 
was observed (a cell viability of 98%). The PI concentration of 0.05 wt% showed enough 
crosslinking and minimal cell death for future experiments. 
3.3. Ultraviolet (UV) Exposure Experiments 
The next series of experiments consisted of GelMA containing 0.05 wt% photoinitiator 
(PI%) exposed to different time periods of ultraviolet (UV) light: 0 s, 100 s, 250 s, 500 s, 





Figure 8. UV wavelength exposure of 500K U87 cells/mL with 0.05 wt % PI at 480 nm, 
1 h post-printing:  A) No UV exposure, B) 100 s UV exposure time, C) 250 s UV 
exposure time, D) 500 s UV exposure time, E) 750 s UV exposure time, and F) 1000 s 
UV exposure time 
 
As observed in Figure 8, each testing condition had a 92 % or greater cell viability, 
with 1000 s having a 93 % cell viability. Additional experiments were conducted with a 
lower concentration of PI (0.01 wt %) to see if a lower PI concentration would increase the 
number of live cells observed compared to the case of 0.05 wt %.  
3.4. Concluding Remarks 
The bioprinting parameters studied here showed the level of control over the process. 
There are other parameters that can affect the quality of our OOACs. The current set up 
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did not include any additional factors such as photo absorbers, or additives such as HA. 
These will have some impact on how the material crosslinks, in particular photo absorbers 
have the potential to be cytotoxic to cells depending on the type used. In our OOAC no 
photo absorbers were used, and the presence of HA has been found to be beneficial to cell 
growth [31], [55].  
The fabrication set up select was the following: ratio of 0.05 wt% PI, 10 s UV exposure, 
7 wt% GelMA and 380 nm wavelength as it resulted in very high cell viability. With the 
experiments conducted, it was concluded that the higher wt% of PI had minimal effect on 
cell viability so the higher concentration was selected in order to decrease printing time. 
Cells had minimal death even with very long exposure times (i.e. 1000 s). It was found that 
the material fully crosslinked for a 1 mm layer within 10 s. Due to this, 10 s exposure was 
selected to cause the least amount of shock to the cells from environmental factors of 







4.1. Monoculture Model 
Initial tests of monoculture controls were performed to ensure that the methods of cell 
encapsulation and seeding would cause minimal cell death. To confirm that cells 
experienced minimal toxicity over a long-term culture, two viability experiments were 
conducted. U87 cells were cultured in 7 wt % crosslinked GelMA over a period of 8 days. 
In addition, human vasculature endothelial cells (HUVECs) were seeded in a channel 
without flow over a period of three days to act as a control for cell behavior in this 
environment. HUVECs were seeded within a 20G needle channel within a crosslinked 
GelMA substrate. As this experiment was conducted without a systolic pump, media 
passively diffused to cells through the porous structure. Due to this there was some concern 
regarding HUVEC viability after 3 days of no media flow. However, as shown in Figure 





Figure 9. Live/Dead fluorescence microscopy images of monocultures:  A) U87 cells 
cultured over 8 days without flow spread and physically interacted; B) HUVEC cells 
cultured over 3 days without flow remained spherical. Shear stress needed for formation 
 
4.2. Co-Culture Experiments 
Minimal death had occurred with cells in a monoculture environment. In order to 
explore a multi-culture environment, a 50:50 co-culture of HUVECs and U87 cells over a 
period of 8 days were conducted. The initial concentration of total cells was 50K cells/mL. 
In the 50:50 culture conditions, cellular composition consisted of equal concentrations of 
25K cells/mL of each cell line. As observed in Figure 10 (B) there appears to be an increase 
in growth observed in the co-culture when compared to the monoculture of U87. This type 
of behavior has been observed in other co-culture studies with cancer and HUVEC cell 
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lines [18]. The presence of HUVEC cells could cause additional proliferation to U87 cells 
resulting in a higher density. 
  
 
Figure 10. 8-day culturing of 50K cells/mL in 7 wt% GelMA:  A) U87, 8-day culture; 
and B) Co-culture sample of 50:50 U87 and HUVECs over 8 days  
 
 
4.3. Microfluidic HUVEC Experiments 
The cellular behavior in which the cells did not attach to the microfluidic channels 
is attributed to no-flow conditions. Since shear flow induces attachment of cells in 
microfluidic channels [16], cellular behavior described above – not attaching in the 
microfluidic channels – is attributed to no-flow conditions, as shear flow induces 
attachment of cells in microfluidic channels [16]. The next step was experimentation of 
seeding cells into a microfluidic channel with multiple days of flow. This was conducted 
to see how well endothelial cells would spread within the channels, and to determine how 
much time it would take this to occur in vitro. Fibronectin (FN) at 1 wt % was added to 
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channels after printing, and before seeding HUVEC cells at 1M cells/mL. The FN-coated 




Figure 11. HUVECs seeded in microfluidic channels, with various days of fluid flow:  A) 
No flow, 5 days; B) Flow, 3 days; C) Flow, 5 days 
 
As observed in Figure 11, as shear flow was introduced, the attachment of the cells 
onto the walls of the microfluidic channels occurred. As more time elapsed, more spreading 
and further attachments of cells onto the walls of the microfluidic channels were observed.  
4.4. Co-Culture Microfluidic Experiments 
The next phase of experimentation utilized GMB disease testing conditions as 
determined from mechanical property experiments.Three testing conditions with differing 
percentages of hyaluronic acid (HA) were selected to represent:  healthy brain tissue (0 % 
HA), mild gliomas (0.1 % HA), and severe gliomas (0.5% HA). %). Two different 
fluorescent tags were selected to tag U87 and HUVECs independently to monitor U87 
metastasis towards HUVEC-lined microfluidic channels. The adopted hypothesis was that 
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as ECM stiffness and HA concentration increased, cellular invasiveness and proliferation 
would increase, resulting in less time for metastasis to occur. In this case, the higher 
concentration of HA, or high-grade gliomas, was hypothesized to have the highest level of 
metastasis. Due to COVID19 evacuations during 2020, experiments were halted in mid-





Conclusions and Future Work 
From this research, we have concluded that glioblastoma cells may contribute to the 
viscoelastic properties of tumors themselves. In addition, in terms of cellularized bioinks 
comprised of GelMA, we may conclude that there is a critical cell density. At this value, 
there is a density in which the shear thinning behavior is enhanced and remains nearly 
constant compared to acellular bioink. This observation was seen with cell densities in the 
range between 0.5M and 5M cells/mL. Density seems to have an effect on shear 
mechanical properties however, cell lines may vary where this critical density lies.[78]. 
We have shown that the customized DLP printer that was developed resulted in 
minimal cell death during the printing process. This was true even with long UV exposure 
(1000 s) as there was greater than 90% cell viability. In addition, the bioink and 
manufacturing composition resulted in high cell viability, verifying the acellular materials 
of the bioink had minimal impact.  
Following literature from past labs [18], [44], a successful co-culture comprising of 
50:50 HUVEC and U87 was conducted. From this, we found that co-culture appears to 
induce GBM proliferation and invasiveness. Current experiments do no show the different 
cell lines present in the culture, as such two different fluorescent stains to mark each cell 
line is suggested. In studies from projects with similar co-culture methods [18], [44], 
similar formation was observed in these initial experiments. This behavior of infusion and 
attachment has been seen in other co-culture cancer models [18], [54].  
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It was planned to have three testing conditions exhibiting mechanical properties from 
different levels of glioblastoma disease progression (health brain, low-grade glioma, high 
grade glioma) [39]. It has been shown in literature HA concentration increases as gliomas 
get more severe, which in turn induces invasiveness of glioblastoma [24], [27]. Additional 
mechanical testing is advised in order to have comparable synthetic ECM mechanical 
properties. This can be done by adjusting the crosslinking time and wt% of GelMA. As HA 
can be produced by cells and would be hard to correlate exact amounts to in vivo it is 
advised to keep the HA wt% the same as initial experiments presented. This is to have a 
replicable synthetic ECM environment to what is seen in vivo. 
 Before the development of the organ-on-a-chip platform, additional tests are suggested 
for the endothelial lined microfluidic channels. An actin and DAPI stain is suggested in 
order to see the location of the cell envelope and location of the endothelial cells in the cell 
lined channels. In addition, a perfusion test is suggested as a secondary test to ensure an 
endothelial barrier is formed. In order to build a better model, it is suggested that 
monitoring shear flow, initial cell density, and how long the channel takes to form should 
be noted in order to ensure the barrier is formed before GBM cells are introduced in a co-
culture model. Further experimentation on bioink ECM properties should be conducted in 
order to create a comparable ECM to forms of the GBM environment. After these bioinks 
and printing parameters are verified, a migration study can be conducted. This is done by 
having an initial tumor location of GBM cells and a HUVEC lined microfluidic channel in 
a co-culture microfluidic system. Monitoring cell line interactions would be done by 
staining each cell line with a different fluorescent stain and monitoring the migration and 
time it takes for the GBM cells to reach a HUVEC lined channel. It is hypothesized that 
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higher elastic modulus and higher HA concentration should result in more invasive 
behavior to occur within a shorter time frame. 
Due to COVID 19, many of these additional and planned experiments could not be 
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